Atomoxetine-related Takotsubo Cardiomyopathy.
Many psychotropic medications target norepinephrine receptors, which can have serious cardiovascular implications, especially in the context of overdoses, polypharmacy, and high-risk populations. This article presents the case of a patient with adult attention-deficit/hyperactivity disorder who developed takotsubo cardiomyopathy subsequent to pharmacokinetic and pharmacodynamic interactions between atomoxetine, a selective norepinephrine reuptake inhibitor, and fluoxetine. Clinicians should be mindful of the potential for cardiovascular adverse effects when prescribing agents that target noradrenergic receptors.
NAGUY: Child and Adolescent Psychiatrist, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait AL-MUTAIRI: Consultant Psychiatrist, Adan Hospital and Director General of Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait AL-TAJALI: General Adult Psychiatrist, Head of Neuromodulation Unit, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait.
Ahmed
A
Naguy
Haya
H
Al-Mutairi
Ali
A
Al-Tajali
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects*; D000328:Adult; D000069445:Atomoxetine Hydrochloride / Q000009:adverse effects*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D004347:Drug Interactions; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects*; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D054549:Takotsubo Cardiomyopathy / Q000139:chemically induced*
D018759:Adrenergic Uptake Inhibitors; D000069445:Atomoxetine Hydrochloride; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors